Do guidelines for treating chest disease in children use Cochrane Reviews effectively? A systematic review

Andrew P. Prayle; Tessy Cox; Sherie J. Smith; Joanne Rycroft-Malone; Kim S. Thomas; Dyfrig A. Hughes; Alan R. Smyth

doi:10.1136/thoraxjnl-2016-208790

Do guidelines for treating chest disease in children use Cochrane Reviews effectively? A systematic review

Andrew P. Prayle^*, Tessy Cox, Sherie J. Smith, Joanne Rycroft-Malone, Kim S. Thomas, Dyfrig A. Hughes, Alan R. Smyth

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

3 Citations (Scopus)

5 Downloads (Pure)

Abstract

Cochrane Reviews summarise best evidence and should inform guidelines. We assessed the use of Cochrane Reviews in the UK guidelines for paediatric respiratory disease. We found 21 guidelines which made 1025 recommendations, of which 96 could be informed by a Cochrane Review. In 38/96 recommendations (40%), some or all of the relevant Cochrane Reviews were not cited. We linked recommendations to 140 Cochrane Reviews. In 37/140 (26%) cases, the guideline recommendation did not fully agree with the Cochrane Review. Guideline developers may fail to use Cochrane Reviews or may make recommendations which are not in line with best evidence.

Original language	English
Pages (from-to)	670-673
Number of pages	4
Journal	Thorax
Volume	73
Issue number	7
Early online date	26 Apr 2017
DOIs	https://doi.org/10.1136/thoraxjnl-2016-208790
Publication status	Published - 01 Jul 2018
Externally published	Yes

Bibliographical note

Funding Information:
Funding This work did not receive specific funding. APP was funded by a NIHR Doctoral Research Fellowship (DRF-2009-02-112), and is currently funded by a NIHR ACL post. DAH receives financial support from the MRC North West Hub in Trial Methodological Research: MR/K025635/1. The funders and sponsor had no involvement in the decision to publish, or the contents of the publication. This report presents independent research funded by the National Institute for Health Research. Competing interests All authors have completed the Unified Competing Interests form at http://www.icmje. org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous 3 years, no other relationships or activities that could appear to have influenced the submitted work. Professor Smyth reports personal fees from Vertex, personal fees from Gilead, personal fees from Roche, personal fees from PTC Therapeutics, outside the submitted work. In addition, Professor Smyth has a patent Alkyl Quinolones as Biomarkers of Pseudomonas aeruginosa Infection and Uses Thereof issued.

Publisher Copyright:
© Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Keywords

Asthma Guidelines
Paediatric Lung Disaese

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine

Access to Document

10.1136/thoraxjnl-2016-208790Licence: CC BY

Do guidelines for treating chest disease in children use Cochrane Reviews effectively? A systematic review
Copyright 2018 the authors. This is an open access article published under a Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.
Final published version, 1.03 MBLicence: CC BY

Cite this

@article{b5ba320b71fa4eedaed9da3657a845b4,

title = "Do guidelines for treating chest disease in children use Cochrane Reviews effectively? A systematic review",

abstract = "Cochrane Reviews summarise best evidence and should inform guidelines. We assessed the use of Cochrane Reviews in the UK guidelines for paediatric respiratory disease. We found 21 guidelines which made 1025 recommendations, of which 96 could be informed by a Cochrane Review. In 38/96 recommendations (40%), some or all of the relevant Cochrane Reviews were not cited. We linked recommendations to 140 Cochrane Reviews. In 37/140 (26%) cases, the guideline recommendation did not fully agree with the Cochrane Review. Guideline developers may fail to use Cochrane Reviews or may make recommendations which are not in line with best evidence.",

keywords = "Asthma Guidelines, Paediatric Lung Disaese",

author = "Prayle, {Andrew P.} and Tessy Cox and Smith, {Sherie J.} and Joanne Rycroft-Malone and Thomas, {Kim S.} and Hughes, {Dyfrig A.} and Smyth, {Alan R.}",

note = "Funding Information: Funding This work did not receive specific funding. APP was funded by a NIHR Doctoral Research Fellowship (DRF-2009-02-112), and is currently funded by a NIHR ACL post. DAH receives financial support from the MRC North West Hub in Trial Methodological Research: MR/K025635/1. The funders and sponsor had no involvement in the decision to publish, or the contents of the publication. This report presents independent research funded by the National Institute for Health Research. Competing interests All authors have completed the Unified Competing Interests form at http://www.icmje. org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous 3 years, no other relationships or activities that could appear to have influenced the submitted work. Professor Smyth reports personal fees from Vertex, personal fees from Gilead, personal fees from Roche, personal fees from PTC Therapeutics, outside the submitted work. In addition, Professor Smyth has a patent Alkyl Quinolones as Biomarkers of Pseudomonas aeruginosa Infection and Uses Thereof issued. Publisher Copyright: {\textcopyright} Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.",

year = "2018",

month = jul,

day = "1",

doi = "10.1136/thoraxjnl-2016-208790",

language = "English",

volume = "73",

pages = "670--673",

journal = "Thorax",

issn = "0040-6376",

publisher = "BMJ Publishing Group",

number = "7",

}

TY - JOUR

T1 - Do guidelines for treating chest disease in children use Cochrane Reviews effectively? A systematic review

AU - Prayle, Andrew P.

AU - Cox, Tessy

AU - Smith, Sherie J.

AU - Rycroft-Malone, Joanne

AU - Thomas, Kim S.

AU - Hughes, Dyfrig A.

AU - Smyth, Alan R.

N1 - Funding Information: Funding This work did not receive specific funding. APP was funded by a NIHR Doctoral Research Fellowship (DRF-2009-02-112), and is currently funded by a NIHR ACL post. DAH receives financial support from the MRC North West Hub in Trial Methodological Research: MR/K025635/1. The funders and sponsor had no involvement in the decision to publish, or the contents of the publication. This report presents independent research funded by the National Institute for Health Research. Competing interests All authors have completed the Unified Competing Interests form at http://www.icmje. org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous 3 years, no other relationships or activities that could appear to have influenced the submitted work. Professor Smyth reports personal fees from Vertex, personal fees from Gilead, personal fees from Roche, personal fees from PTC Therapeutics, outside the submitted work. In addition, Professor Smyth has a patent Alkyl Quinolones as Biomarkers of Pseudomonas aeruginosa Infection and Uses Thereof issued. Publisher Copyright: © Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Cochrane Reviews summarise best evidence and should inform guidelines. We assessed the use of Cochrane Reviews in the UK guidelines for paediatric respiratory disease. We found 21 guidelines which made 1025 recommendations, of which 96 could be informed by a Cochrane Review. In 38/96 recommendations (40%), some or all of the relevant Cochrane Reviews were not cited. We linked recommendations to 140 Cochrane Reviews. In 37/140 (26%) cases, the guideline recommendation did not fully agree with the Cochrane Review. Guideline developers may fail to use Cochrane Reviews or may make recommendations which are not in line with best evidence.

AB - Cochrane Reviews summarise best evidence and should inform guidelines. We assessed the use of Cochrane Reviews in the UK guidelines for paediatric respiratory disease. We found 21 guidelines which made 1025 recommendations, of which 96 could be informed by a Cochrane Review. In 38/96 recommendations (40%), some or all of the relevant Cochrane Reviews were not cited. We linked recommendations to 140 Cochrane Reviews. In 37/140 (26%) cases, the guideline recommendation did not fully agree with the Cochrane Review. Guideline developers may fail to use Cochrane Reviews or may make recommendations which are not in line with best evidence.

KW - Asthma Guidelines

KW - Paediatric Lung Disaese

U2 - 10.1136/thoraxjnl-2016-208790

DO - 10.1136/thoraxjnl-2016-208790

M3 - Review article

AN - SCOPUS:85028748823

SN - 0040-6376

VL - 73

SP - 670

EP - 673

JO - Thorax

JF - Thorax

IS - 7

ER -

Do guidelines for treating chest disease in children use Cochrane Reviews effectively? A systematic review

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this